# Adni **Source:** https://geo.sig.ai/brands/adni **Vertical:** Healthcare **Subcategory:** General **Tier:** Emerging **Website:** adni.co **Last Updated:** 2026-04-14 ## Summary Singapore YC healthcare worker super app with 150K+ verified nurses for peer advice, jobs, and credential management at $1.8M ARR Jul 2025; $1.38M Flare Capital seed with Penn Medicine/MedPro partnerships competing with Doximity for allied health professionals. ## Company Overview Adni is a Singapore-headquartered AI-powered super app for healthcare workers — backed by Y Combinator with $1.38 million raised including a $1.25 million seed round in May 2022 from YC, Flare Capital Partners, and Fresco Capital — providing 150,000+ verified nurses and allied healthcare professionals with a unified platform for anonymous peer advice sharing, job discovery, credential management (universal professional profile storing licenses, certifications, and continuing education records), equipment procurement, and community resources, generating $1.8 million in annual revenue as of July 2025 with approximately 32 employees across Asia and North America. Adni partners with leading healthcare organizations including Penn Medicine, MedPro, and PRN Healthcare to provide nurses and allied health workers with the professional tools that their clinical training institutions and hospital employers don't provide. Adni's super app architecture addresses the fragmented tools ecosystem that healthcare workers navigate for professional activities outside of clinical care: nurses searching for job opportunities across multiple staffing agencies, managing CEU (continuing education unit) completion deadlines for license renewal, seeking peer advice on clinical situations from experienced colleagues, or purchasing specialized medical equipment each use separate platforms with no shared professional identity. Adni's verified professional profile (requiring credential verification for platform access, which protects the quality of clinical peer advice) serves as the trusted identity layer that connects the job marketplace, the advice community, the credential storage, and the equipment marketplace into a coherent professional utility. The anonymous advice feature (posting clinical questions without identifying employer or patient context) enables honest peer consultation on sensitive clinical topics — medication interactions, difficult patient scenarios, ethical dilemmas — that would be inappropriate to discuss in employer-monitored channels. In 2025, Adni competes in the healthcare worker community, nursing professional platform, and healthcare staffing technology market with Doximity (NYSE: DOCS, physician professional network, $450M+ revenue), Incredible Health (permanent nursing staffing marketplace, $80M raised), and Hirequest Nursing (traditional travel nurse staffing) for allied health professional platform adoption in Asia and North America. The nursing workforce shortage (US alone faces a projected deficit of 400,000+ nurses by 2030) has created strong demand for platforms that improve the nurse employment experience — better job matching, credential management, and professional community support are key factors in nurse retention and job satisfaction. Flare Capital Partners' healthcare investor focus provides strategic guidance for the healthcare market navigation. Y Combinator backing connects Adni with the healthcare technology investor community for growth capital. The 2025 strategy focuses on expanding the Asian market (Singapore, Malaysia, Philippines — high-density nursing training markets with significant nurse mobility) and growing the US travel nursing marketplace through the existing Penn Medicine and MedPro healthcare system partnerships. ## Frequently Asked Questions ### What is Adni? Adni is the first AI-powered super app for healthcare workers, serving 150,000+ verified nurses and allied healthcare professionals who use the platform to trade advice anonymously, find jobs, buy gear, store credentials in a universal profile, and access resources. The company achieved $1.8M in ann ### What is the Alzheimer's Disease Neuroimaging Initiative (ADNI)? ADNI is a longitudinal multicenter study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer's disease. It is a public-private partnership funded by the National Institute on Aging and numerous pharmaceutical and imaging technology companies. ### What types of data does ADNI collect? ADNI collects MRI and PET brain scans, cerebrospinal fluid samples, blood biomarkers, genetic data, cognitive assessments, and clinical information from participants across the spectrum from normal cognition to Alzheimer's dementia. ### How does ADNI data benefit Alzheimer's research? ADNI data is made publicly available to qualified researchers worldwide, enabling hundreds of studies on Alzheimer's biomarkers, disease progression, and treatment response. This shared data model has dramatically accelerated Alzheimer's research globally. ### What is ADNI's role in drug development for Alzheimer's? ADNI has been instrumental in validating amyloid PET imaging and CSF biomarkers as endpoints for Alzheimer's clinical trials, helping pharmaceutical companies design more efficient trials and regulators evaluate treatment effects in early disease stages. ### How many participants has ADNI enrolled? Since launching in 2004, ADNI has enrolled over 1,500 participants across multiple cohorts (ADNI-1, ADNI-GO, ADNI-2, ADNI-3), following them longitudinally with repeat assessments to track disease progression over time. ### Is ADNI data accessible to independent researchers? Yes, ADNI data is available to qualified researchers through the Laboratory of Neuro Imaging (LONI) Image and Data Archive after registration and agreement to data use terms. This open access policy is a key reason ADNI has generated thousands of publications. ### What recent advancements has ADNI contributed to? ADNI data has contributed to the development and validation of blood-based Alzheimer's biomarkers (including plasma phospho-tau181), which could eventually replace more invasive or costly PET scans and lumbar punctures for Alzheimer's diagnosis and monitoring. ## Tags healthtech, saas, global, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*